The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
about
Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosisSubcutaneous rapid-acting insulin analogues for diabetic ketoacidosisIntensive glucose control versus conventional glucose control for type 1 diabetes mellitusShort-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitusComing of age: the artificial pancreas for type 1 diabetesInsulin degludec and insulin aspart: novel insulins for the management of diabetes mellitusPharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study.Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wearAccelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidasePlasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?Metabolic Control With the Bio-inspired Artificial Pancreas in Adults With Type 1 Diabetes: A 24-Hour Randomized Controlled Crossover Study.Safety and effectiveness of insulin aspart in Basal-bolus regimens regardless of age: a1chieve study results.Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis.Clinical Effects and Safety of Direct-Acting Insulin Analogs in Patients with Type 1 Diabetes: A Nation-Wide Observational Cohort Study.Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Insulin biosimilars: the impact on rapid-acting analogue-based therapy.Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices.Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons.Insulin analogues in type 1 diabetes mellitus: getting better all the time.Management of Glycemia in Acute Febrile IllnessAssessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel sPeripheral IV Insulin Infusion Infiltration Presenting as "Insulin Resistance".Impact of Single or Repeated Dose Intranasal Zinc-free Insulin in Young and Aged F344 Rats on Cognition, Signaling, and Brain Metabolism.Short acting insulin analogues in intensive care unit patients.Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes.Pharmacokinetics and pharmacodynamics of insulin glargine-insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals.A review of reviews: a virtual issue.Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes.Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart.EADSG Guidelines: Insulin Therapy in Diabetes.Lispro administered by the QS-M Needle-Free Jet Injector generates an earlier insulin exposure.Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis.A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus.Efficacy and safety of the artificial pancreas in the paediatric population with type 1 diabetes.
P2860
Q24186409-A90E5601-0286-4FD7-868C-D56A199AE9DFQ24194201-5D18D328-8779-4330-9050-2C4EC94A003FQ24200376-33EE3787-7C82-429C-8EC6-751A769F5FF4Q26471380-D3CA9FB3-4B59-4819-ACB4-E6D24518E495Q26745886-2CB7E627-C707-4738-8F68-5499D4E17DE9Q26777076-12BB456A-22DC-4555-8DD4-FF6E0029DB65Q33658772-1D011498-07A3-494F-A086-1E05B8285A7AQ33814995-9345D0A2-A1C3-41BB-8F6D-515149B2BC35Q35929406-5DFB9786-90BA-4307-BC93-3396E821E3AFQ36229271-8567A102-7987-45A8-8327-69C17BB64015Q36554243-D306B0B5-DA38-4D91-828C-7E9D79F33372Q36638921-B9956A80-2F7E-45EA-9031-EEB26168268BQ36941696-C58B1EA6-312E-463C-8236-5805B2706738Q36941721-9EB163F3-8C95-4131-8395-CD95133138D5Q37239321-50482594-1204-4040-9BD2-35E8C83559E4Q37633455-11917CAE-2925-45CA-B8A5-957133DA6FF2Q37742600-409B1AA5-D409-4E59-816C-351531937DE2Q38241834-0B7034AA-F1FF-42C8-A7ED-2405F8FE2FE4Q38379020-92D5E969-36D8-4BD3-BA1E-7525EA7B5A6DQ38578266-AAAA5EB6-0EDF-489F-AD84-FBEE8AFF1DAFQ38652925-F139F902-1860-4475-8C02-37F45D2FAB16Q38692387-9236C2AD-3AAB-4E19-865F-C03CD5AC4D8BQ39335834-715F3A0B-7C8A-447E-B1AD-22E39F3026BAQ39436182-5AC18386-706A-441D-9002-E8294A3DC65CQ39500153-9DE48FDB-ADD9-433F-B790-CC6692CDD0D1Q39858501-33CC1616-F79A-434A-9AF0-EC221B5AE24AQ40743447-7E07051B-2245-4A28-8B6D-E54469A63E85Q41172888-103054D4-9951-4374-BAC9-787FD108A99FQ45729286-582913D7-120B-4BAD-96FA-A88950F78727Q45891354-BBAC57FB-8DA8-4DD2-9DC6-C6EA7C845331Q47443616-D9742F75-DE64-4F43-BEB1-17366BBAC27EQ48361256-DCF2D9FF-37A3-4DA9-A774-9C0C37AEBF5DQ51245935-492980D8-E2CC-47DA-9757-35108E2FEA87Q51302693-9E843E8F-A6FE-4325-9143-9DFC750F615FQ55107366-06DDD399-4CA7-4619-9677-78A54B5FF863Q55162068-FFA4A3B2-BCF3-415E-800F-E978881E33E6Q55514033-F095338A-9054-460D-AA29-0D1976D44146
P2860
The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The pharmacokinetics and pharm ...... d their clinical consequences.
@en
The pharmacokinetics and pharm ...... d their clinical consequences.
@nl
type
label
The pharmacokinetics and pharm ...... d their clinical consequences.
@en
The pharmacokinetics and pharm ...... d their clinical consequences.
@nl
prefLabel
The pharmacokinetics and pharm ...... d their clinical consequences.
@en
The pharmacokinetics and pharm ...... d their clinical consequences.
@nl
P2860
P1476
The pharmacokinetics and pharm ...... d their clinical consequences.
@en
P2093
P2860
P304
P356
10.1111/J.1463-1326.2012.01580.X
P577
2012-03-09T00:00:00Z